Can Oncolytic Viruses be the key to Treat Resistant Tumors?

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline.

targovax logo

City: Oslo, Norway

Founded: 2010

Employees: 20 – 30

Financial data: €12M raised in a private placement in July

Øystein Soug, CEO

Mission: Targovax develops immuno-oncology therapies for treatment-resistant solid tumors. Its lead program TG01, currently in Phase II, uses a peptide-based immunotherapy to target T-cell MHC II receptors in pancreatic cancer. On the other hand, there’s ONCOS-102, an adenovirus therapy to boost the immune response now in Phase I for mesothelioma and melanoma.

Comment: Targovax’s ambitious plan is to launch 4 new trials this year to test the effects of ONCOS-102 in combination with checkpoint inhibitors, chemotherapy or a dendritic cell vaccine to treat melanoma, mesothelioma, ovarian cancer and prostate cancer. We wish them luck!

Featured image: Labiotech map


Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More